NASDAQ:LOXO - Loxo Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$180.47 +1.30 (+0.73 %)
(As of 06/20/2018 03:45 AM ET)
Previous Close$179.17
Today's Range$175.25 - $180.86
52-Week Range$69.00 - $208.95
Volume478,500 shs
Average Volume458,541 shs
Market Capitalization$5.32 billion
P/E Ratio-33.99
Dividend YieldN/A
Beta2.45
Loxo Oncology logoLoxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LOXO
CUSIPN/A
Phone203-653-3880

Debt

Debt-to-Equity RatioN/A
Current Ratio3.52
Quick Ratio3.52

Price-To-Earnings

Trailing P/E Ratio-33.99
Forward P/E Ratio225.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.30 million
Price / Sales254.86
Cash FlowN/A
Price / CashN/A
Book Value$12.63 per share
Price / Book14.29

Profitability

EPS (Most Recent Fiscal Year)($5.31)
Net Income$-148,870,000.00
Net MarginsN/A
Return on Equity-21.73%
Return on Assets-14.55%

Miscellaneous

Employees59
Outstanding Shares30,080,000

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. During the same quarter in the previous year, the firm earned ($0.96) EPS. View Loxo Oncology's Earnings History.

What price target have analysts set for LOXO?

12 brokers have issued twelve-month price objectives for Loxo Oncology's shares. Their forecasts range from $122.00 to $235.00. On average, they expect Loxo Oncology's stock price to reach $180.3333 in the next twelve months. View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (5/8/2018)
  • 2. Cann analysts commented, "Loxo’s Q4:17 loss per share was $0.69 compared to our estimated loss of $1.18. The lower than estimated loss resulted from collaboration revenue recognition of $21.3 million. This was partially offset by operating expenses being 17.9% higher than estimated. Higher operating expenses arose primarily from higher R&D. As a result, we are increasing our estimated R&D expenses for 2018 and 2019. There were no other remarkable variances in the quarter. The completion of the rolling NDA submission for larotrectinib is expected in March 2018, and the Marketing Authorization Application submission in the EU is expected in 2018. This submission is being led by Bayer." (3/1/2018)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 46)
  • Ms. Jennifer Burstein, Sr. VP of Fin. (Age 46)
  • Mr. Jacob S. Van Naarden, Chief Bus. Officer (Age 33)
  • Ms. Sara Slifka, VP of Bus. Operations & Program Management
  • Ms. Jennifer L. Kronick, VP of HR

Has Loxo Oncology been receiving favorable news coverage?

News coverage about LOXO stock has been trending somewhat negative this week, Accern reports. Accern identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Loxo Oncology earned a media sentiment score of -0.02 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 40.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.04%), OppenheimerFunds Inc. (3.49%), ACCESS INDUSTRIES MANAGEMENT, LLC (2.85%), Lord Abbett & CO. LLC (2.22%), Victory Capital Management Inc. (1.48%) and Rock Springs Capital Management LP (1.05%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

Which major investors are selling Loxo Oncology stock?

LOXO stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., DAFNA Capital Management LLC, Eventide Asset Management LLC, Prudential Financial Inc., BlackRock Inc., Candriam Luxembourg S.C.A., OppenheimerFunds Inc. and JPMorgan Chase & Co.. Company insiders that have sold Loxo Oncology company stock in the last year include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Insider Buying and Selling for Loxo Oncology.

Which major investors are buying Loxo Oncology stock?

LOXO stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frontier Capital Management Co. LLC, KBC Group NV, Federated Investors Inc. PA, American Century Companies Inc., UBS Group AG, Sei Investments Co. and Mackay Shields LLC. View Insider Buying and Selling for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $180.47.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $5.32 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (LOXO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.